Regeneron Pharmaceuticals is investing $800 million in Alnylam Pharmaceuticals to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference technology.
Scores of clinics across the United States directly advertise expensive – but unproven – cell therapy procedures to patients with serious eye diseases, often with devastating results, a new study warns.
ProQR Therapeutics N.V. announced that the company received Fast Track designation from the Food and Drug Administration for QR-421a for Usher syndrome type 2.
Genentech announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.
